HER2/neu peptide vaccine: Phase I ongoing

TapImmune Inc. (OTCBB:TPIV, Seattle, Wash.) said an open-label Phase I trial of intradermal HER2/neu peptide vaccine will continue following an interim safety analysis of the first 5 patients, which ...